SANTA ROSA, Calif., Sept. 21 /PRNewswire/ -- Osseon Therapeutics announced today that its Osseoflex (steerable and curvable bone cement delivery needle) and Osseoflex DR (steerable and curvable bone drill) systems for percutaneous vertebral augmentation received CE Mark approval for marketing and clinical use in the European Union.
The Osseoflex systems employ a proprietary steerable access device to symptomatically correct acute fractures of the spinal vertebrae. These are seen in hundreds of thousands of patients annually, most commonly due to osteoporosis but also resulting from trauma or malignancy. The ability to access the entire vertebra through a single point of access reduces procedure time and decreases risk compared to systems requiring multiple points of access. This advantage, in turn, provides not only reliable clinical benefit, but reduces costs to hospitals, payors and ultimately patients. The Osseoflex systems, in conjunction with the proprietary Osseoperm biocompatible cement system have been in clinical use in the United States since December 2008. Data from nearly 400 patients at multiple centers in thirty states confirm the efficiency and efficacy of the Osseon system, with most patients treated as an outpatient with excellent pain relief.
Osseon website: http://www.osseon.com/
SOURCE Osseon Therapeutics, Inc.
CONTACT: Michael Bivens, Marketing Director of Osseon Therapeutics, Inc.,
+1-503-475-3333, michael.bivens@osseon.com
Web site: http://www.osseon.com/
